Vor Biopharma Inc (NAS:VOR)

$ 1.81 0.01 (0.56%) Market Cap: 123.55 Mil Enterprise Value: 50.13 Mil PE Ratio: 0 PB Ratio: 1.00 GF Score: 35/100

Vor Biopharma Inc at Chardan Genetic Medicines Conference Transcript
Oct 02, 2023
Vor Biopharma Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Vor Biopharma Inc at Goldman Sachs Healthcare Conference Transcript
Jun 12, 2023
Vor Biopharma Inc Annual Shareholders Meeting Transcript
May 26, 2023
Vor Biopharma Inc at Barclays Global Healthcare Conference Transcript
Mar 15, 2023
Vor Biopharma Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Vor Biopharma Inc at B Riley Securities Oncology Conference (Virtual) Transcript
Jan 18, 2023
PureTech Health PLC Medical Research Update Transcript
Dec 07, 2022
Vor Biopharma Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Dec 01, 2022
Vor Biopharma Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022
Vor Biopharma Inc at Stifel Healthcare Conference Transcript
Nov 16, 2022
Vor Biopharma Inc at Credit Suisse Healthcare Conference Transcript
Nov 08, 2022
Vor Biopharma Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022
Vor Biopharma Inc Annual Shareholders Meeting Transcript
Jun 14, 2022
Vor Biopharma Inc at B Riley Oncology Conference (Virtual) Transcript
Jan 27, 2022
Vor Biopharma Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 11, 2021

Vor Biopharma Inc at Stifel Healthcare Conference Transcript

Nov 16, 2022 / 03:20PM GMT

Release Date Price: $4.5 (-2.39%)

Transcript 10-Q

Stephen Willey

Stifel Financial Corp. - Analyst

Editor

(audio in progress) we have Nathan Jorgensen, who is the Chief -- I'm Stephen Willey, one of the senior biotech analysts here at Stifel, and glad to have with us here for the next session Vor Biopharma.

With us and to my left, we have Nathan Jorgensen, who is the Chief Financial Officer. We have Tirtha Chakraborty, who is the Chief Scientific Officer. I think some of you may have seen that Robert Ang was scheduled to present here, but I believe he's been taken out.

So appreciate you guys making the trip. And we're going to have just kind of an informal discussion around the state of things that Vor. If anyone has a question, feel free to raise your hand. We'll try to get it asked and addressed.

Nathan, not sure if you want to make any kind of opening comments before we get into Q&A [in order].

Nathan Jorgensen

Vor Biopharma, Inc. - CFO

I'll just say thank you for having us here, Steve. It's a pleasure to be back here at Stifel. And it's

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.